Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-05-15 00:00:00 ET · period of report 2025-05-13 · accession 0000875320-25-000196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-15 | 2025-05-13 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +37.6K | 100.6K | +60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-13 | A | A | 37,622 | $0.00 | 100,611 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 12/06/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/13/2025 and the shares will vest on 07/01/2025. |